Literature DB >> 7908128

Effects of tryptamine on plasma glucagon levels in mice.

J Yamada1, Y Sugimoto, I Kimura, Y Watanabe, K Horisaka.   

Abstract

Our previous study indicated that tryptamine induces a dose-related increase in plasma glucagon levels of mice and that this effect is mediated by the peripheral serotonin2 (5-HT2) receptor. The present paper further investigated the involvement of serotonergic and catecholaminergic systems in hyperglucagonemia elicited by tryptamine. An inhibitor of 5-HT synthesis, p-chlorophenylalanine, did not affect tryptamine-induced increases in plasma glucagon levels. Tryptamine-induced hyperglucagonemia was not inhibited by adrenalectomy or by an inhibition of catecholamine synthesis by alpha-methyl-p-tyrosine. These findings indicate that tryptamine-induced hyperglucagonemia is elicited by its direct activation of 5-HT2 receptors and is not mediated by levels of endogenous 5-HT and catecholamines. The results further suggest that the peripheral 5-HT2 receptor has a possible role in the release of glucagon.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7908128     DOI: 10.1007/bf00966722

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  16 in total

1.  The evidence for the involvement of the 5-HT1A receptor in 5-HT syndrome induced in mice by tryptamine.

Authors:  J Yamada; Y Sugimoto; K Horisaka
Journal:  Jpn J Pharmacol       Date:  1989-11

2.  Pharmacological analysis of the variation in behavioural responses to tryptamine in five strains of mice.

Authors:  J Yamada; Y Sugimoto; K Horisaka
Journal:  Eur J Pharmacol       Date:  1987-08-21       Impact factor: 4.432

3.  The activation of serotonin receptors by tryptamine induces hyperinsulinemia in mice.

Authors:  J Yamada; Y Sugimoto; I Kimura; N Takeuchi; K Horisaka
Journal:  Eur J Pharmacol       Date:  1990-06-08       Impact factor: 4.432

4.  p-chlorophenylalanine attenuates the pituitary-adrenocortical response to 5-HT1A receptor agonists in mice.

Authors:  T Matsuda; T Kanda; Y H Seong; A Baba; H Iwata
Journal:  Eur J Pharmacol       Date:  1990-06-08       Impact factor: 4.432

5.  Hypothermia induced in mice by intracerebroventricular injection of tryptamine: involvement of the 5-HT1 receptor.

Authors:  J Yamada; H Wakita; Y Sugimoto; K Horisaka
Journal:  Eur J Pharmacol       Date:  1987-07-02       Impact factor: 4.432

6.  The behavioural effects of intravenously administered tryptamine in mice.

Authors:  J Yamada; Y Sugimoto; K Horisaka
Journal:  Neuropharmacology       Date:  1987-01       Impact factor: 5.250

7.  Hyperglucagonemia induced in mice by tryptamine: involvement of the peripheral 5-HT2 receptors.

Authors:  J Yamada; Y Sugimoto; I Kimura; Y Watanabe; N Takeuchi; K Horisaka
Journal:  Eur J Pharmacol       Date:  1992-06-05       Impact factor: 4.432

8.  Tryptamine: a neuromodulator or neurotransmitter in mammalian brain?

Authors:  R S Jones
Journal:  Prog Neurobiol       Date:  1982       Impact factor: 11.685

9.  Production of anti-glucagon sera with a C-terminal fragment of pancreatic glucagon.

Authors:  K Imagawa; T Nishino; S Shin; S Uehata; E Hashimura; C Yanaihara; N Yanaihara
Journal:  Endocrinol Jpn       Date:  1979-02

10.  Serotonin-induced hypoglycemia and increased serum insulin levels in mice.

Authors:  J Yamada; Y Sugimoto; I Kimura; N Takeuchi; K Horisaka
Journal:  Life Sci       Date:  1989       Impact factor: 5.037

View more
  2 in total

1.  Tryptamine induces tryptophanyl-tRNA synthetase-mediated neurodegeneration with neurofibrillary tangles in human cell and mouse models.

Authors:  Elena L Paley; Galina Denisova; Olga Sokolova; Natalia Posternak; Xukui Wang; Anna-Liisa Brownell
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

2.  Inhibitory effects of tryptamine on tolbutamide-induced hypoglycemia in mice: mediation by 5-HT receptors.

Authors:  Y Sugimoto; J Yamada; I Kimura; Y Watanabe; K Horisaka
Journal:  Neurochem Res       Date:  1994-01       Impact factor: 3.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.